Home R&D/Novel modulator of anti-PD1 response>
Latest News
See all news

R&D

Novel modulator of anti-PD1 response

We have discovered a novel potent regulator of anti-PD-1 therapy in syngeneic mouse models harboring resistance to PD-1 immune checkpoint inhibitor. Neutralization of this target markedly improves the efficacy of anti-PD-1 mAb therapy by increasing the response rates and by increasing the rate of complete vs partial responses, which results in improved survival. We have generated various human-mouse cross-reactive blocking antibodies, including a humanized lead mAb. The mAb is currently under preclinical development as a novel immunotherapeutic antibody to overcome resistance to anti-PD-1 immune checkpoint blockade.

Events
See all events